Bigger Capital and District 2 Capital Issue White Paper in Support of DCVax-L, a Second-Generation Autologous Dendritic Cell Vaccine
In-depth Analysis of Northwest Biotherapeutics' Cancer Vaccine by an Expert in Cellular and Molecular Medicine Trained at the Johns Hopkins School of Medicine and the Ludwig Center for Cancer Genetics and Therapeutics
DCVax-L Interim Efficacy and Safety are Impressive, Clinical Manufacturing is a Surmountable Challenge, and the Regulatory Environment for GBM, a Deadly Disease with Severe Unmet Need, is Favorable
Northwest Biotherapeutics May be a Severely Discounted Cancer Immunotherapy Company
HUNTINGTON, N.Y., Nov. 15, 2018 /PRNewswire/ -- Bigger Capital Fund, LP and District 2 Capital Fund LP, together with their affiliates (collectively, the "Funds"), hedge funds that invest primarily in biotechnology companies, announce that Carlo Rago, PhD, who has an extensive background in the biotechnology industry, authored a white paper in support of DCVax-L, a second-generation autologous dendritic cell vaccine, produced by Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"). The white paper focuses on the potential value of the therapeutic platform the Company has created. The paper considers, among other things, the benefits dendritic cell vaccines are beginning to produce for cancer patients and their role as an important tool for cancer immunotherapy strategies. The paper reviews DCVax-L's phase III interim results in newly diagnosed glioblastoma ("GBM") patients and highlights what Dr. Rago believes is an underappreciated detail that suggests the vaccine may be operating through the proposed mechanism, dendritic cell activation of T cells against cancer-specific antigens.
The white paper entitled: "A Second-Generation Dendritic Cell Cancer Vaccine Preparing to Shine" is available at the following links:
http://biggercapital.squarespace.com/storage/value/NWBO%20-%20White%20Paper%20Rago_48081593.pdf
Based on Dr. Rago's assessment about the viability of DCVax-L, the Funds believe the current trading price of the Company's securities is not reflective of their value. As indicated below, the Funds and Dr. Rago own securities of the Company. They may also engage in future transactions with respect to securities of the Company, including both purchases and sales.
About Bigger Capital Fund, LP and District 2 Capital Fund LP: Bigger Capital Fund, LP ("Bigger Capital") and District 2 Capital Fund LP ("District 2 Capital") are research intensive hedge funds that invest primarily in Biotechnology. The Funds are affiliated entities. Bigger Capital commissioned Dr. Rago to author the white paper.
Carlo Rago, PhD – currently serves as a Biotechnology consultant including to the Funds. Dr. Rago received his PhD in Cellular and Molecular Medicine at The Johns Hopkins University School of Medicine and conducted a post-doctoral fellowship at the Johns Hopkins Ludwig Center for Cancer Genetics and Therapeutics. He was the Chief Scientific Officer and Co-Founder of DMD Therapeutics, Inc., a Co-Founder and the Scientific Director of the Duchenne Alliance, Scientific Director of Ryan's Quest, and Founder and Chief Executive Officer of OpenOnward.
Dr. Rago will be attending the Annual Meeting and Education Day of the Society for Neuro-Oncology in New Orleans on November 15-18, 2018, and will be available to answer questions about the white paper.
Disclosures
Carlo Rago, PhD owns Northwest Biotherapeutics Common Stock. In addition, Dr. Rago serves as a Consultant to Bigger Capital and District 2 Capital. Dr. Rago's compensation depends on the performance of the securities in the Funds' portfolio. The Funds own Common Stock and Warrants of Northwest Biotherapeutics.
This press release may contain forward-looking statements, including statements as to anticipated or expected results, beliefs, opinions, and future financial performance. The forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that may cause the Company's actual experience to differ materially from that anticipated.
The views contained in this press release and the white paper referenced herein represent the opinions of the Funds and Dr. Rago as of the date hereof based solely on publicly available information and do not represent medical or investment advice in any way. In addition, the efficacy and safety of DCVax-L is only one element in valuing the securities of the Company. Investors and other interested parties of the Company are encouraged to do their own analysis of DCVax-L and the Company. Each of the Funds and Dr. Rago reserves the right to change any of its or his opinions expressed herein or in the white paper at any time and for any reason and expressly disclaims any obligation to correct, update or revise the information contained herein or in the white paper. The information contained in this press release and the white paper may not contain all of the information required in order to evaluate the value of the Company or its securities. Investors should seek independent scientific or financial advice regarding the efficacy and safety of DCVax-L, the suitability of investing in any securities or of following any investment strategies; neither the Funds nor Dr. Rago is offering or providing such services in connection with this press release or the white paper or otherwise making a recommendation to buy or sell any of the Company's securities.
Contact
Bigger Capital at https://twitter.com/biggercapital
Carlo Rago, PhD at https://twitter.com/rago_carlo or https://www.linkedin.com/in/carlo-rago-7695151/
SOURCE Bigger Capital Fund, LP
Share this article